Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676114 | 0.77 | PTGER4 (0.56) | GRM5GRM4PTGER4L3MBTL1ATM | |
| SCHEMBL16625722 | 0.76 | GPR3 (0.50) | PTGER4L3MBTL1GPR3MEN1KMT2A | |
| SCHEMBL678729 | 0.75 | PDE10A (0.50) | PTGER4L3MBTL1GPR3MEN1KMT2A | |
| SCHEMBL679421 | 0.73 | L3MBTL1 (0.49) | GRM5GRM4L3MBTL1ATMTDP1 | |
| SCHEMBL679430 | 0.71 | ALK (0.44) | GRM5GRM4L3MBTL1ATMTDP1 | |
| SCHEMBL1609982 | 0.71 | GPR3 (0.52) | L3MBTL1GPR3PDE10A | |
| SCHEMBL9903456 | 0.71 | GRM5 (1.00) | GRM5GRM4 | |
| SCHEMBL16607405 | 0.69 | GRM4 (1.00) | GRM4 | |
| SCHEMBL280139 | 0.69 | GPR3 (0.58) | L3MBTL1NPC1RAB9AGPR3PDE10A | |
| SCHEMBL18381782 | 0.67 | GPR3 (0.56) | L3MBTL1NPC1RAB9AGPR3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | GRM5 3229/4885GRM4 3998/4885PTGER4 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.